Report interim data readout from PDS01ADC plus HAIP therapy trial in colorectal and gallbladder cancer
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Feb 2025
- Due
- 30 Jun 2026
- Delivered
- 15 Apr 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Interim data readout: PDS01ADC + HAIP therapy in colorectal & gall bladder cancer”
What we found
Evidence strength A What the grades mean
PDS Biotechnology published interim Phase 2 data for PDS01ADC + HAIP therapy in colorectal cancer liver metastases on April 15, 2026, before the Q2 2026 deadline.
-
A PDS Biotechnology Corp - Form 8-K - FY2026 SEC 8-K filing with interim trial data on PDS01ADC + HAIP in colorectal cancer
-
B PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial Company press release announcing interim data readout for colorectal cohort
-
D Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial Peer-reviewed publication of the interim Phase 2 trial data
-
D PDS Biotech (NASDAQ: PDSB) spotlights PDS0101 Phase 3 and IL-12 ADC Investor slide showing separate catalysts for colorectal vs cholangiocarcinoma cohorts
Checked 18 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you PDS Biotechnology Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-PDSB-000230 · Corrections policy